Search results
Showing 256 to 270 of 308 results for behaviour change
This guideline covers safe and effective use of medicines in health and social care for people taking 1 or more medicines. It aims to ensure that medicines provide the greatest possible benefit to people by encouraging medicines reconciliation, medication review, and the use of patient decision aids.
Excess winter deaths and illness and the health risks associated with cold homes (NG6)
This guideline covers reducing the health risks (including preventable deaths) associated with living in a cold home. It aims to improve the health and wellbeing of people vulnerable to the cold. Improving the temperature in homes, by improving energy efficiency, may also help reduce unnecessary fuel consumption.
This guideline covers recognising, assessing and treating post-traumatic stress disorder (PTSD) in children, young people and adults. It aims to improve quality of life by reducing symptoms of PTSD such as anxiety, sleep problems and difficulties with concentration. Recommendations also aim to raise awareness of the condition and improve coordination of care.
This quality standard covers support and treatment to stop smoking and stop using smokeless tobacco, and harm-reduction approaches for people who are not ready to stop in one go. It describes high-quality care in priority areas for improvement.
View quality statements for QS207Show all sections
Sections for QS207
- Quality statements
- Quality statement 1: Identifying people who use tobacco
- Quality statement 2: Advice
- Quality statement 3: Tobacco cessation support and treatment
- Quality statement 4: Harm-reduction approach
- Quality statement 5: Treatment to stop smoking in hospital
- Update information
- About this quality standard
Evidence-based recommendations on peginterferon alfa (Pegasys; ViraferonPeg) and ribavirin (Copegus) for treating chronic hepatitis C in children and young people.
NICE has developed a medtech innovation briefing (MIB) on 24/7 EEG SubQ for epilepsy .
This guideline covers diagnosing and managing cystic fibrosis. It specifies how to monitor the condition and manage the symptoms to improve quality of life. There are also detailed recommendations on treating the most common infections in people with cystic fibrosis.
skin conductance, patient satisfaction, changes in adaptive function, quality of life and disruptive behaviour. Adverse...
children and young people at risk of attachment difficulties and changes in behaviour in response to an attachment-based...
MRI-based technologies for assessing non-alcoholic fatty liver disease (HTG655)
Evidence-based recommendations on MRI-based technologies for assessing non-alcoholic fatty liver disease.
of life influences information sharing, advanced care planning and the behaviour of healthcare professionals. A mixed-methods approach...
NICE has developed a Medtech Innovation Briefing (MIB) on the SENSIMED Triggerfish contact lens sensor for continuous 24-hour recording of ocular dimensional
This guideline covers indoor air quality in residential buildings. It aims to raise awareness of the importance of good air quality in people's homes and how to achieve this.
NICE has developed a medtech innovation briefing (MIB) on Smartinhaler for asthma .
This quality standard covers care and treatment for adults (aged 18 and over) with type 1 diabetes. It describes high-quality care in priority areas for improvement.
View quality statements for QS208Show all sections
Sections for QS208
- Quality statements
- Quality statement 1: Structured education programmes
- Quality statement 2: Continuous glucose monitoring
- Quality statement 3: Statin therapy for primary prevention of cardiovascular disease
- Quality statement 4: 9 key care processes
- Quality statement 5: Assessing the risk of diabetic foot problems on admission to hospital
- Quality statement 6: Support to self-manage diabetes during inpatient admissions
- Quality statement 7 (placeholder): Identification of eating disorders in adults with type 1 diabetes